<p>Alnylam Pharmaceuticals Inc. has announced a new five-year strategy, “Alnylam 2030,” aimed at scaling operations and driving long-term growth. Key components of the strategy include establishing and maintaining leadership in ATTR amyloidosis, investing in the expansion of its RNAi therapeutics pipeline, and focusing on sustainable innovation. The company plans to file Investigational New Drug (IND) applications for three to four new Alnylam-led programs by the end of 2026 and report Phase 1 data in the second half of the year. Alnylam has provided 2026 net product revenue guidance of $4.9 billion to $5.3 billion, primarily driven by total TTR net product revenues of $4.4 billion to $4.7 billion. The strategy emphasizes financial discipline and operational agility to support efficient scaling and continued growth. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-001755), on January 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

ALNY

Reuters

Alnylam Pharma

Alnylam Pharmaceuticals Unveils "Alnylam 2030" Strategy Focusing on Expanding ATTR Amyloidosis Leadership, Advancing Pipeline Programs, and Projecting Significant Revenue Growth Through 2026